Keymed Biosciences Inc
Company Profile
Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHNT: +86 2888610620
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,258
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,586.70 | 15.30 | 0.18% |
| CAC 40 | 7,854.58 | 9.86 | -0.13% |
| DAX 40 | 24,104.63 | 105.46 | 0.44% |
| Dow JONES (US) | 41,859.09 | 1.35 | -0.00% |
| FTSE 100 | 8,762.11 | 22.85 | 0.26% |
| HKSE | 23,601.26 | 56.95 | 0.24% |
| NASDAQ | 18,925.73 | 53.09 | 0.28% |
| Nikkei 225 | 37,160.47 | 174.60 | 0.47% |
| NZX 50 Index | 12,596.50 | 65.75 | -0.52% |
| S&P 500 | 5,842.01 | 2.60 | -0.04% |
| S&P/ASX 200 | 8,360.90 | 12.20 | 0.15% |
| SSE Composite Index | 3,348.37 | 31.82 | -0.94% |